Ideaya Biosciences Inc (IDYA)

$28.12 -0.01 (-0.04%)
Market Cap 2.47B
Revenue (ttm) 218.71M
Net Income (ttm) -113.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -51.99%
Debt to Equity Ratio 0.00
Volume 726,800
Avg Vol 1,260,856
Day's Range N/A - N/A
Shares Out 87.86M
Stochastic %K 25%
Beta -0.04
Analysts Strong Sell
Price Target $52.38

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also o...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 443 6209
Address:
5000 Shoreline Court, Suite 300, South San Francisco, United States
brunoq14
brunoq14 May. 13 at 12:34 PM
$IDYA Briefly above 29, now below 28.
0 · Reply
Hottehueh
Hottehueh May. 12 at 5:13 PM
$IDYA soon...
0 · Reply
CH_Expat
CH_Expat May. 12 at 4:11 PM
$IDYA Just a little more ball kicking on low volume. The SWTX, BPMC and ARWR treatment for longs. The perfect stock to master your emotions.
2 · Reply
hegdaom
hegdaom May. 12 at 1:29 AM
$IDYA $XBB $IBB
0 · Reply
ripztrip
ripztrip May. 11 at 6:37 PM
$IDYA WHY the Lag Exists Several factors explain why the stock hasn't yet priced in the full upside despite bullish data: Topline ≠ Full Data: The April 13 release was just topline PFS data. The ASCO presentation on June 1 will deliver depth-of-response, subgroup analyses, durability, and safety granularity — details that regulators and physicians need, and that drive NDA filings. "Buy the rumor, sell the news" risk: Some traders may have taken gains after the April 13 pop, creating a reset opportunity before ASCO $XBB $IBB
2 · Reply
SauceMan912
SauceMan912 May. 11 at 6:21 PM
$IDYA need your gains wiped out daily? Look no further. Boy do I have the stock for you 🤦🏼‍♂️🤣 this thing is such a joke. I think it’s almost time to move on and chalk this up as the dud of all duds.
1 · Reply
SauceMan912
SauceMan912 May. 8 at 6:43 PM
$IDYA shocker… 1.5% drop in 30 minutes to take it back red. Honestly this stock has become laughable at this point with its daily price action. 🤦🏼‍♂️🤣
1 · Reply
CH_Expat
CH_Expat May. 8 at 2:52 PM
$IDYA Most new holders will be happy when this one day hits high 30s. They will feel like they dodged a bullet and sell after months of pain and hunger games with a small gain. Once this happens, the real run will begin.
4 · Reply
hegdaom
hegdaom May. 8 at 1:44 PM
$CAPR Retail got stopped out last night. thats why its very dangerous to set stop loss orders in the after hours!!!! $SRPT $XBI $IBB $IDYA
0 · Reply
himsssss
himsssss May. 8 at 10:40 AM
$IDYA Thousands of share deep in this still. (3200)
0 · Reply
Latest News on IDYA
IDEAYA Biosciences Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 8:00 PM EDT - 13 hours ago

IDEAYA Biosciences Transcript: Bank of America Global Healthcare Conference 2026

Ideaya Biosciences price target lowered to $50 from $52 at Mizuho

2026-05-07T15:52:20.000Z - 5 days ago

Ideaya Biosciences price target lowered to $50 from $52 at Mizuho

Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)

2026-05-05T10:23:24.000Z - 8 days ago

Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 6:00 AM EDT - 8 days ago

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026, 6:00 AM EDT - 12 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA

2026-04-30T10:37:31.000Z - 13 days ago

Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

Apr 30, 2026, 6:00 AM EDT - 13 days ago

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

Apr 21, 2026, 10:15 AM EDT - 21 days ago

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

Ideaya Biosciences price target raised to $58 from $52 at Wedbush

2026-04-14T13:25:59.000Z - 4 weeks ago

Ideaya Biosciences price target raised to $58 from $52 at Wedbush

Ideaya Biosciences price target raised to $54 from $50 at Guggenheim

2026-04-14T11:37:36.000Z - 4 weeks ago

Ideaya Biosciences price target raised to $54 from $50 at Guggenheim

Ideaya Biosciences price target raised to $53 from $49 at RBC Capital

2026-04-14T11:20:51.000Z - 4 weeks ago

Ideaya Biosciences price target raised to $53 from $49 at RBC Capital

Ideaya Biosciences price target raised to $65 from $60 at Truist

2026-04-13T18:15:11.000Z - 4 weeks ago

Ideaya Biosciences price target raised to $65 from $60 at Truist

Ideaya Biosciences rises 22.8%

2026-04-13T14:06:36.000Z - 4 weeks ago

Ideaya Biosciences rises 22.8%

IDEAYA Biosciences Transcript: Study result

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

IDEAYA Biosciences Transcript: Study result

Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results

Apr 13, 2026, 7:21 AM EDT - 4 weeks ago

Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results

Ideaya Biosciences, Servier announce topline results from OptimUM-02 trial

2026-04-13T10:19:08.000Z - 4 weeks ago

Ideaya Biosciences, Servier announce topline results from OptimUM-02 trial

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

Apr 13, 2026, 6:00 AM EDT - 4 weeks ago

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

Apr 10, 2026, 4:05 PM EDT - 4 weeks ago

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

Unusually active option classes on open April 8th

2026-04-08T13:47:57.000Z - 4 weeks ago

Unusually active option classes on open April 8th

ALK ALLY BKNG IBB KWEB SCO VEA

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

Apr 6, 2026, 6:00 AM EDT - 5 weeks ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

Ideaya Biosciences announces first-patient-in for IDE849, IDE161 study

2026-03-30T10:12:31.000Z - 6 weeks ago

Ideaya Biosciences announces first-patient-in for IDE849, IDE161 study

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

Mar 30, 2026, 6:00 AM EDT - 6 weeks ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release

2026-03-23T14:30:40.000Z - 7 weeks ago

Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release

Ideaya Biosciences falls -6.0%

2026-03-23T14:06:29.000Z - 7 weeks ago

Ideaya Biosciences falls -6.0%

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

Mar 22, 2026, 10:00 AM EDT - 7 weeks ago

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs

Mar 18, 2026, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs

Ideaya Biosciences enrolls first patient in IDE892 trial

2026-03-09T10:05:16.000Z - 2 months ago

Ideaya Biosciences enrolls first patient in IDE892 trial

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

Mar 9, 2026, 6:00 AM EDT - 2 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

Citi opens ‘upside 90-day catalyst watch’ on Ideaya Biosciences

2026-03-06T11:41:06.000Z - 2 months ago

Citi opens ‘upside 90-day catalyst watch’ on Ideaya Biosciences

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Feb 27, 2026, 7:00 PM EST - 2 months ago

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Ideaya Biosciences enrolls first patient in IDE034 trial

2026-02-25T11:20:31.000Z - 2 months ago

Ideaya Biosciences enrolls first patient in IDE034 trial

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

Feb 25, 2026, 6:00 AM EST - 2 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

IDEAYA Biosciences Transcript: Status update

Feb 23, 2026, 12:00 PM EST - 2 months ago

IDEAYA Biosciences Transcript: Status update

Ideaya Biosciences appoints Theodora Ross as chief development officer

2026-02-23T11:12:03.000Z - 2 months ago

Ideaya Biosciences appoints Theodora Ross as chief development officer

ABBV

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

Feb 23, 2026, 6:00 AM EST - 2 months ago

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

Ideaya Biosciences price target raised to $65 from $64 at Citi

2026-02-19T11:50:19.000Z - 2 months ago

Ideaya Biosciences price target raised to $65 from $64 at Citi

IDEAYA Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Feb 18, 2026, 1:00 PM EST - 2 months ago

IDEAYA Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit

Ideaya Biosciences price target raised to $52 from $49 at Wedbush

2026-02-18T13:17:02.000Z - 2 months ago

Ideaya Biosciences price target raised to $52 from $49 at Wedbush

Ideaya Biosciences reports Q4 EPS (94c), consensus (95c)

2026-02-17T11:11:10.000Z - 3 months ago

Ideaya Biosciences reports Q4 EPS (94c), consensus (95c)

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Feb 17, 2026, 6:00 AM EST - 3 months ago

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events

Feb 2, 2026, 6:00 AM EST - 3 months ago

IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events

IDEAYA Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 4 months ago

IDEAYA Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 12:00 PM EST - 4 months ago

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 6:00 AM EST - 4 months ago

IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

Dec 11, 2025, 6:00 AM EST - 5 months ago

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

Dec 10, 2025, 6:00 AM EST - 5 months ago

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

Dec 4, 2025, 7:00 PM EST - 5 months ago

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

IDEAYA Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 10:50 AM EST - 5 months ago

IDEAYA Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

IDEAYA Biosciences Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 9:00 AM EST - 5 months ago

IDEAYA Biosciences Transcript: Citi Annual Global Healthcare Conference 2025

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

Dec 1, 2025, 6:00 AM EST - 5 months ago

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

Nov 24, 2025, 6:00 AM EST - 6 months ago

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

IDEAYA Biosciences Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:00 AM EST - 6 months ago

IDEAYA Biosciences Transcript: Jefferies London Healthcare Conference 2025

IDEAYA Biosciences Transcript: Citi's 2025 SMID Cap Biopharma Call Series

Nov 6, 2025, 12:00 PM EST - 6 months ago

IDEAYA Biosciences Transcript: Citi's 2025 SMID Cap Biopharma Call Series

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

Oct 27, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

Oct 20, 2025, 6:30 AM EDT - 7 months ago

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Oct 20, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

Sep 8, 2025, 8:00 AM EDT - 8 months ago

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences Transcript: R&D Day 2025

Sep 8, 2025, 8:00 AM EDT - 8 months ago

IDEAYA Biosciences Transcript: R&D Day 2025

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

Sep 8, 2025, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Sep 7, 2025, 12:00 PM EDT - 8 months ago

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

Sep 4, 2025, 6:00 AM EDT - 8 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

IDEAYA Biosciences Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:10 AM EDT - 9 months ago

IDEAYA Biosciences Transcript: Cantor Global Healthcare Conference 2025

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Sep 3, 2025, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Sep 2, 2025, 6:00 AM EDT - 9 months ago

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Aug 29, 2025, 2:00 PM EDT - 9 months ago

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

Aug 25, 2025, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

Aug 18, 2025, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

Jul 24, 2025, 9:25 AM EDT - 10 months ago

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

Jul 23, 2025, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Jul 22, 2025, 1:01 PM EDT - 10 months ago

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

Jul 21, 2025, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

IDEAYA Biosciences Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

IDEAYA Biosciences Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

IDEAYA Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

IDEAYA Biosciences Transcript: Jefferies Global Healthcare Conference 2025

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

Jun 2, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

IDEAYA Biosciences Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 8:30 AM EDT - 1 year ago

IDEAYA Biosciences Transcript: RBC Capital Markets Global Healthcare Conference 2025

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 6:05 AM EDT - 1 year ago

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

May 6, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

Apr 28, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

Apr 14, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

Apr 10, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences Transcript: RBC Inaugural Virtual Ophthalmology Conference

Apr 3, 2025, 11:30 AM EDT - 1 year ago

IDEAYA Biosciences Transcript: RBC Inaugural Virtual Ophthalmology Conference

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

Apr 1, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

Mar 31, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

brunoq14
brunoq14 May. 13 at 12:34 PM
$IDYA Briefly above 29, now below 28.
0 · Reply
Hottehueh
Hottehueh May. 12 at 5:13 PM
$IDYA soon...
0 · Reply
CH_Expat
CH_Expat May. 12 at 4:11 PM
$IDYA Just a little more ball kicking on low volume. The SWTX, BPMC and ARWR treatment for longs. The perfect stock to master your emotions.
2 · Reply
hegdaom
hegdaom May. 12 at 1:29 AM
$IDYA $XBB $IBB
0 · Reply
ripztrip
ripztrip May. 11 at 6:37 PM
$IDYA WHY the Lag Exists Several factors explain why the stock hasn't yet priced in the full upside despite bullish data: Topline ≠ Full Data: The April 13 release was just topline PFS data. The ASCO presentation on June 1 will deliver depth-of-response, subgroup analyses, durability, and safety granularity — details that regulators and physicians need, and that drive NDA filings. "Buy the rumor, sell the news" risk: Some traders may have taken gains after the April 13 pop, creating a reset opportunity before ASCO $XBB $IBB
2 · Reply
SauceMan912
SauceMan912 May. 11 at 6:21 PM
$IDYA need your gains wiped out daily? Look no further. Boy do I have the stock for you 🤦🏼‍♂️🤣 this thing is such a joke. I think it’s almost time to move on and chalk this up as the dud of all duds.
1 · Reply
SauceMan912
SauceMan912 May. 8 at 6:43 PM
$IDYA shocker… 1.5% drop in 30 minutes to take it back red. Honestly this stock has become laughable at this point with its daily price action. 🤦🏼‍♂️🤣
1 · Reply
CH_Expat
CH_Expat May. 8 at 2:52 PM
$IDYA Most new holders will be happy when this one day hits high 30s. They will feel like they dodged a bullet and sell after months of pain and hunger games with a small gain. Once this happens, the real run will begin.
4 · Reply
hegdaom
hegdaom May. 8 at 1:44 PM
$CAPR Retail got stopped out last night. thats why its very dangerous to set stop loss orders in the after hours!!!! $SRPT $XBI $IBB $IDYA
0 · Reply
himsssss
himsssss May. 8 at 10:40 AM
$IDYA Thousands of share deep in this still. (3200)
0 · Reply
hegdaom
hegdaom May. 8 at 4:13 AM
$IDYA
0 · Reply
forprofit12
forprofit12 May. 7 at 7:56 PM
$IDYA added
0 · Reply
SauceMan912
SauceMan912 May. 7 at 4:52 PM
$IDYA oh whatttyaknow…. Red again. My goodness I don’t think I’ve ever seen this stock go up. What a disaster.
0 · Reply
sv__
sv__ May. 7 at 3:31 PM
$IDYA The waiting game here is nothing compared to what I've been experiencing at SLS and NUVB. Nothing's changed. Easy buy and hold. Patience is my middle name. 😁
0 · Reply
CH_Expat
CH_Expat May. 7 at 3:04 PM
$IDYA People who know me can confirm I am never a pumper. But this stock is manipulated through the roof. Price movement is exactly the same since 10 days. Volume between 600k and 1.2m. Start low of day, stay flat, some buys and volume before the bell. Shareholders of ARWR in the teens and SWTX in the twens will know what I am talking about. Some vicious extra selloffs, f.e. at ASCO on OS-Signals, could be the icing of the cake. I will not give them my shares.
2 · Reply
CH_Expat
CH_Expat May. 6 at 6:19 PM
$IDYA The hunger games. Are you frustrated? I bet you are. Am I frustrated? Sure I am. But I know my made my biggest gains in setups like these (BPMC at 38, TARS at 22, SWTX at 28) and this gives me inner strength. Especially BPMC went a very similar price way. Hunger games for months on excellent news.
0 · Reply
brunoq14
brunoq14 May. 6 at 5:15 AM
$IDYA I thought this was starting to rally today. Nope.
1 · Reply
CH_Expat
CH_Expat May. 5 at 6:25 PM
$IDYA I added another 400. This is all nuts. I really tried hard and even if IDE397, IDE894 and IDE034 would ALL fail, we would still be undervalued. Serious games here. Todays press release is nothing but positive.
4 · Reply
4Reel
4Reel May. 5 at 2:04 PM
$IDYA amazing that this is the new standard of care for HLA A2 negative after the excellent phase 3 results. And fda has agreed to RTOR and this still continues down every day. Not going anywhere as this is now one of the top 5 values in all of biotech. And thats just based on the negative. They will probably havr good resukts for the postive as well just how good plus the rest of their pipeline and partners.
1 · Reply
hegdaom
hegdaom May. 5 at 1:27 PM
$IDYA
0 · Reply
DasBrinkus
DasBrinkus May. 5 at 1:00 PM
$IDYA https://ir.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update
1 · Reply
DasBrinkus
DasBrinkus May. 4 at 9:58 PM
$IDYA what is someone doing? $31 AH?! 🤣
1 · Reply